Cerenome Reports Preliminary REYOBIQ Safety and Efficacy Data

Cerenome (CNSY) reported interim data for REYOBIQ, showing no dose-limiting toxicities in 10 patients with leptomeningeal metastases. One patient had Grade 3 nausea. No leptomeningeal progression was seen at 3 or 6 months. Analysts have a $12.00 price target, but Spark rates it Neutral due to financial and technical concerns.

Original reporting
Published Nov 16, 2026, 1:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 1:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$CNSY
Bullish
medium confidence
Mentioned
$CNSY
Relevance
8/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$CNSYBullishMed
01

Why it matters

The interim safety data reduce perceived risk, potentially prompting short‑term buying pressure, but the limited efficacy information keeps upside capped.

02

Market read

First disclosure of trial safety data for a micro‑cap biotech; may trigger short‑term price movement.

03

What to watch

Small sample size and short follow‑up; regulatory hurdles for radiopharma remain high.

Relevance 8/10Novelty 8/10Timing: same day release

Background

Cerenome (CNSY) is a CNS oncology company developing precision diagnostics and radiopharmaceuticals. REYOBIQ is its lead therapeutic candidate.

Company-level read

Ticker impact

$CNSYBullishMedium confidence
Context

Cerenome disclosed interim safety and efficacy data for its REYOBIQ radiopharmaceutical in leptomeningeal metastases, showing no dose‑limiting toxicities in the first 10 patients.

Expected impact

likely modest upside as market prices in the favorable safety profile

Evidence & confidence

The data are preliminary but show no serious adverse events, which is uncommon for early CNS radiopharma trials and could attract speculative interest.

Market effects

Early positive data may improve perception of CNS‑focused radiopharmaceuticals and benefit peer biotech companies.

US biotech micro‑caps could see heightened attention.

Limited to niche oncology investors; broader market impact minimal.

Counterpoint

Data set is very small and lacks survival outcomes; investors may view it as insufficient to justify price gains.

Key entities

  • Cerenome, Inc.

    Developer of REYOBIQ radiopharmaceutical for CNS cancers.

Related articles

$CNSYMedAI 8/10

Cerenome (CNSY) Q3 2026 Earnings Call Transcript

Cerenome (CNSY) reported Q3 2026 earnings, highlighting progress in diagnostics and therapeutics. CNSide Diagnostics is on track for 1,250 annualized tests and exceeded 150M covered lives. REYOBIQ trials are advancing, with Phase II enrollment completed for ReSPECT-GBM and interim data presented for ReSPECT-LM. The company aims for mid-2027 top-line data and FDA alignment for next steps.

$CNSYMedAI 8/10

Cerenome Shares Interim REYOBIQ Data At SNO Meeting; Phase 2 Study Targeted For 2027

Cerenome (CNSY) presented interim Phase 1 data for REYOBIQ at the SNO meeting, showing no dose-limiting toxicities in 10 patients. Imaging confirmed consistent radiation delivery, and no LM progression was seen in evaluable patients at 3 and 6 months. REYOBIQ was generally well-tolerated. The company plans a Phase 2 study in 2027, subject to progress and regulatory alignment.

$CNSYMedAI 8/10

Cerenome Reports Interim REYOBIQ Data: No Dose-Limiting Toxicities in First 10 Patients

Cerenome reported interim data from the ReSPECT-LM study, showing no dose-limiting toxicities in the first 10 patients treated with REYOBIQ. One patient received three doses totaling 79.2 mCi, with consistent radiation delivery. No leptomeningeal (LM) progression was observed at three or six months, with one case at nine months. Cerenome plans a Phase 2 study in 2027, pending regulatory alignment.

$CNSYMedAI 8/10

Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting

CERENOME, INC. (CNSY) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting No dose-limiting toxicities in the first 10 patients; consistent and reliable dosing of a targeted radiopharmaceutical; early di